Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Briquilimab - Jasper Therapeutics

Next Previous
Drug Profile

Briquilimab - Jasper Therapeutics

Alternative Names: AMG-191; JSP-191

Latest Information Update: 25 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen; National Heart, Lung and Blood Institute; Stanford University
  • Developer Amgen; Jasper Therapeutics; Tectonic Therapeutic
  • Class Anti-inflammatories; Antiallergics; Antianaemics; Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic urticaria
  • Phase I Allergic asthma
  • Preclinical Anaphylaxis; Atopic dermatitis; Fabry's disease; Gaucher's disease
  • Discontinued Inflammation; Myelodysplastic syndromes

Most Recent Events

  • 14 Aug 2026 Jasper Therapeutics plans a pre-BLA meeting with the US FDA
  • 14 Aug 2026 Jasper Therapeutics plans to submit a BLA
  • 06 Aug 2026 Jasper Therapeutics terminates a phase II trial for Chronic urticaria in Germany and USA (SC, Injection) due to changes in company priorities and not due to safety concerns (NCT06736262)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top